ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor
(Thomson Reuters ONE) -
Leuven, Belgium - 05 March, 2015 - ThromboGenics NV (Euronext Brussels: THR), an
integrated biopharmaceutical company focused on developing and commercializing
innovative medicines for the treatment of vitreo-retinal diseases, is pleased to
announce that Joseph Markoff, Ph.D., M.D. has joined the Company as Scientific
Advisor. Dr. Markoff will report to Paul G. Howes, Executive Chairman of
ThromboGenics Inc., and work with the Medical Affairs team in the U.S. and the
global Clinical Development team.
Dr. Markoff has over 35 years of experience as an ophthalmic surgeon at the
Wills Eye Hospital in Philadelphia, PA. He has directed the hospital's Visual
Physiology service for the past 32 years and also holds the rank of Attending
Surgeon and Clinical Professor of Ophthalmology at Thomas Jefferson University
Medical School.
Dr. Markoff founded Philadelphia Eye Associates, a leading private eye care
practice in the Philadelphia area. From February 2010 till recently, he assumed
the role as Global Director for Scientific Affairs in Ophthalmology at Merck &
Co., Inc.
Dr. Markoff has conducted over 50 clinical trials during his career sponsored by
companies such as Alcon, Allergan, Pfizer, Pharmacia and Merck & Co.
Paul Howes, Executive Chairman of ThromboGenics, Inc. said: "Joseph Markoff adds
vast experience and knowledge in ophthalmology, particularly in the retinal
space, to the ThromboGenics team. I expect his expertise to prove hugely
valuable as we roll-out the results of on-going real-world clinical studies on
treatment of symptomatic VMA with JETREA(® )and embark on new indications such
as diabetic retinopathy."
END
For further information please contact:
+------------------------------------------+-----------------------------------+
| | |
|ThromboGenics |Citigate Dewe Rogerson |
| | |
|Wouter Piepers, |David Dible/ Malcolm Robertson |
|Global Head of Corporate Communications &| |
|IR |Tel: +44 20 7638 9571 |
|+32 16 75 13 10 / +32 478 33 56 32 |malcolm.robertson(at)citigatedr.co.uk |
|wouter.piepers(at)thrombogenics.com | |
| | |
+------------------------------------------+-----------------------------------+
About ThromboGenics
ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic and oncology medicines. The Company's
lead product, JETREA(® )(ocriplasmin), has been approved by the US FDA for the
treatment of symptomatic VMA and was launched in January 2013.
ThromboGenics signed a strategic partnership with Alcon, a division of Novartis,
for the commercialization of JETREA(®) outside the United States.
ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ
(US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels
exchange under the symbol THR. More information is available at
www.thrombogenics.com.
About JETREA(® )(ocriplasmin)
JETREA(® )(ocriplasmin) is a truncated form of human plasmin. In the US,
JETREA(®) is indicated for the treatment of symptomatic VMA. In Europe,
JETREA(®) is indicated for the treatment of vitreomacular traction (VMT),
including when associated with macular hole of diameter less than or equal to
400 microns. JETREA(®) is a selective proteolytic enzyme that cleaves
fibronectin, laminin and collagen, three major components of the vitreoretinal
interface that play an important role in vitreomacular adhesion.
JETREA(® )has been evaluated in two multi-center, randomized, double-masked
Phase III trials conducted in the U.S. and Europe involving 652 patients with
vitreomacular adhesion. Both studies met the primary endpoint of resolution of
VMA at day 28.
JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin
saw resolution of VMA, compared with 10.1% of patients receiving placebo
(p<0.01). The Phase III program also showed that JETREA was generally well
tolerated with most adverse events being transient and mild in severity.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: ThromboGenics NV via GlobeNewswire
[HUG#1899820]
Unternehmensinformation / Kurzprofil:
Datum: 05.03.2015 - 15:33 Uhr
Sprache: Deutsch
News-ID 376498
Anzahl Zeichen: 7023
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 151 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor"
steht unter der journalistisch-redaktionellen Verantwortung von
ThromboGenics NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
